OVV-01

AXP000132.1 · Oncolytic virus

Platform
vesicular stomatitis virus (recombinant, NY-ESO-1-armed)

Names

NameTypeSource
OVV-01preferred name, codecurator, ctgov
C045 ambiguouscodectgov
oncolytic virus (OVV-01) injectionsynonymctgov

Virus

Role
Oncolytic
Family
Rhabdoviridae
Virus
vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
Strain
Indiana, recombinant
Replication
replicating
Modifications
recombinant VSV engineered for selective replication in tumour cells (details not published)
Transgenes
NY-ESO-1 (CTAG1B)
Route
intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07650838OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS)Not yet recruitingPhase 22026-08-012027-12-3140Soft Tissue Sarcoma (STS)
NCT07650825OVV-01 Intravenous and Intratumoral Injection Combined With AK112 for the Treatment of Advanced Solid TumorsNot yet recruitingPhase 12026-08-012027-01-3130Advanced Solid Tumors
NCT07648472A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.RecruitingPhase 12026-04-212027-04-2018Advanced Solid Tumors
NCT05271279A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant TumorsTerminatedEarly phase 12021-12-242022-08-292Advanced Solid Tumor; Relapsed/Refractory Lymphoma
NCT04787003Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid TumorsUnknownPhase 12021-02-162023-10-0150Neoplasms

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40480657Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors.Journal for immunotherapy of cancer2025cited by trial NCT04787003

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 40873562Mechanism of action of over-expressing NY-ESO-1 in vesicular stomatitis virus and its combination therapy with NY-ESO-1 TCR-T.Frontiers in immunology2025name in abstract: OVV-01

Notes

Genetically engineered oncolytic VSV expressing the tumour antigen NY-ESO-1; first-in-human phase 1 NCT04787003 dosed 18 patients intratumorally (Hua et al., J Immunother Cancer 2025, PMID 40480657). Trial code C045. Commercial developer not named in the registration or the paper abstract; left empty.

How to cite

OVV-01 (AXP000132.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000132.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.